CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Optimize the management of chronic lymphocytic leukemia through the rational integration of prospective pivotal data sets.
  • Counsel patients with follicular lymphoma about recent advances in induction and maintenance systemic treatment.
  • Efficiently apply the results of emerging clinical research to the care of patients with myelodysplastic syndromes and acute myeloid leukemia.
  • Recall the expanding body of evidence for the use of arsenic trioxide in the management of acute promyelocytic leukemia, and incorporate this agent, when appropriate, into evidence-based treatment algorithms.
  • Outline the classification of T-cell lymphomas, and formulate up-to-date treatment strategies for patients with diverse subtypes of the disease.
  • Employ an understanding of recent findings with proteasome inhibitors and immunomodulatory agents in individualized induction and maintenance therapy for patients with multiple myeloma.
  • Describe the biologic rationale, efficacy and toxicity of novel agents targeting CD30-positive Hodgkin lymphoma and anaplastic large cell lymphoma.
  • Facilitate patient access to clinical trial participation through communication of ongoing research opportunities.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Cheson — Advisory Committee: Allos Therapeutics, Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company; Consulting Agreement: Millennium — The Takeda Oncology Company. Dr Gore — Consulting Agreement, Paid Research and Stock Ownership: Celgene Corporation. Dr Foss — Advisory Committee: Allos Therapeutics; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Eisai Inc. Dr Niesvizky — Advisory Committee, Consulting Agreements and Paid Research: Celgene Corporation, Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium — The Takeda Oncology Company.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi-Aventis and Seattle Genetics.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: May 2011
  Expiration date: May 2012